Moving PARP Inhibition Upfront: Why the Phase 3 TALAPRO-3 Trial Rewrites Treatment for HRR-Deficient mCSPC

Reflow Medical’s Retrievable Coronary Drug‑Eluting Stent Shows Early Promise in In‑Stent Restenosis

Reflow Medical’s retrievable sirolimus-eluting coronary scaffold aims to treat in-stent restenosis without permanent metal, potentially improving vessel healing while preserving future treatment options.

Neurovalens CEO Outlines Noninvasive Neuromodulation Plans

Neurovalens’ Modius platform brings noninvasive neuromodulation into clinical practice, offering home-based FDA-authorized therapies for insomnia, anxiety, PTSD, and weight management, while facing evidence, reimbursement, and adoption challenges.

Shifting Care in Acute Leukemia: The Dawn of Menin Inhibition

Menin inhibitors revumenib and ziftomenib target key leukemia-driving mutations, improving remission rates, enabling transplant opportunities, and advancing precision treatment for relapsed acute leukemias.

Clinician Adoption of AI to Detect LV Systolic Dysfunction in Everyday Practice

AI-powered ECG and ultrasound tools can identify silent left ventricular systolic dysfunction earlier, enabling timely evaluation, targeted treatment, and improved heart failure prevention and outcomes.

How Oral TKIs are Rewriting the Frontline and Pretreated Landscape in HER2-Mutant NSCLC

A new generation of oral HER2-targeted therapies is transforming advanced NSCLC care, delivering durable responses, brain metastasis control, and personalized treatment beyond traditional chemotherapy.